Senti Biosciences Holdings, Inc. has announced a significant change in its financial oversight by dismissing KPMG LLP as its independent registered public accounting firm. The decision, effective November 17, 2026, was made by the company's Audit Committee. This move comes at a critical time for the company as it continues to face financial difficulties.

Founded in Delaware and operating in the biological products sector, Senti Biosciences focuses on developing innovative therapies. The company, which trades under the ticker symbol SNTI on the Nasdaq, has undergone several changes in its corporate structure, including a reorganization that took effect in April 2026. This restructuring aimed to enhance its operational efficiency and financial stability.

According to the recent SEC filing, the dismissal of KPMG was approved by the Audit Committee, which oversees the company's financial reporting and compliance. KPMG had served as the independent auditor for Senti Biosciences and its predecessor, Senti Biosciences, Inc., for several years. The audit reports from KPMG for the fiscal years ending December 31, 2025, and 2024, did not contain adverse opinions but did raise concerns about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

The filing indicates that there were no disagreements between Senti and KPMG regarding accounting principles or practices during the audit periods. However, a material weakness in the company's internal control over financial reporting was noted, which has since been addressed. The Audit Committee discussed this issue with KPMG prior to their dismissal.

On November 20, 2026, the Audit Committee approved the engagement of KNAV CPA LLP as the new independent registered public accounting firm for Senti Biosciences. This change reflects the company's commitment to improving its financial oversight as it navigates ongoing challenges in the competitive biological products industry.

The transition to KNAV is particularly noteworthy given the recent scrutiny on Senti's financial health. The company has been working to remediate its financial reporting processes, and the new auditor will play a crucial role in ensuring compliance and transparency moving forward. The decision to change auditors may signal to investors and stakeholders that Senti is taking proactive steps to strengthen its financial governance.

As Senti Biosciences continues to adapt to its evolving business landscape, the impact of this auditor transition will be closely monitored by industry analysts and competitors alike. The biological products sector is known for its rapid advancements and competitive pressures, making effective financial oversight essential for success.

The filing does not specify what further actions will follow this change in auditors, leaving stakeholders eager for updates on how Senti will address its financial challenges under new oversight.